Journal of Neuro-Oncology

, Volume 137, Issue 2, pp 429–438 | Cite as

Clinical and dosimetric study of radiotherapy for glioblastoma: three-dimensional conformal radiotherapy versus intensity-modulated radiotherapy

  • David Thibouw
  • Gilles TrucEmail author
  • Aurélie Bertaut
  • Cédric Chevalier
  • Léone Aubignac
  • Céline Mirjolet
Clinical Study


Background and purpose

We aimed to compare three-dimensional conformal radiotherapy (3D-CRT) with intensity-modulated radiotherapy (IMRT) for the treatment of glioblastoma.

Materials and methods

Retrospective study of 220 patients with glioblastoma, treated with 3D-CRT or IMRT, with or without surgery. Dosimetric parameters as well as clinical and survival data for the two techniques were analyzed and compared.


The median conformity index was 1.53 (range 0–2.69) for 3D-CRT and 1.25 (range 0.97–2.01) for IMRT, p < 10−4. The median homogeneity index was 0.10 (range 0.03–0.32) for 3D-CRT and 0.07 (range 0.03–0.18) for IMRT, p < 10−4. There were significantly fewer acute grade 1 and 2 neurological toxicities in the IMRT group especially for edema (1.3 versus 12.4%, p = 0.017), concentration disorders (6.6 versus 19.9%, p = 0.003) and consciousness disorders (2.6 versus 13.2%, p = 0.002) although IMRT patients had a significantly worse pre-treatment neurological status than 3D-CRT patients. Median survival was 16.0 months (range 11.9–17.8) for IMRT and 13.4 months (range 11.7–15.7) for 3D-CRT patients (p = 0.542).


IMRT improved target conformity and reduced neurological toxicities for patients with glioblastomas.


Glioblastoma Intensity-modulated radiation therapy 3D conformational radiation therapy Dosimetric outcomes Clinical outcomes 



We would like to thank Philip Bastable for his review and corrections of the wording in this manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

For this type of retrospective study, formal consent is not required.

Supplementary material

11060_2017_2735_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 18 kb)
11060_2017_2735_MOESM2_ESM.docx (21 kb)
Supplementary material 1 (DOCX 21 kb)


  1. 1.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996.CrossRefGoogle Scholar
  2. 2.
    Truc G, Bernier V, Mirjolet C, Dalban C, Mazoyer F, Bonnetain F et al (2016) A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. Cancer Radiother 20(3):193–198CrossRefGoogle Scholar
  3. 3.
    Chen Y-D, Feng J, Fang T, Yang M, Qiu X-G, Jiang T (2013) Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme. Chin Med J (Engl) 126(12):2320–2324Google Scholar
  4. 4.
    Amelio D, Lorentini S, Schwarz M, Amichetti M (2010) Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. Radiother Oncol J Eur Soc Ther Radiol Oncol 97(3):361–369CrossRefGoogle Scholar
  5. 5.
    Chan MF, Schupak K, Burman C, Chui C-S, Ling CC (2003) Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim Off J Am Assoc Med Dosim 28(4):261–265Google Scholar
  6. 6.
    Cao Y, Tseng C-L, Balter JM, Teng F, Parmar H, Sahgal A et al (2017) MR-guided radiation therapy: transformative technology and its role in the central nervous system. Neuro Oncol 19(2):16–29CrossRefGoogle Scholar
  7. 7.
    Kanas V, Zacharaki E, Thomas G, Zinn PColen R et al (2017) Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma. Comput Methods Prog Biomed 140(2):249–257CrossRefGoogle Scholar
  8. 8.
    Ghose A, Lim G, Husain S (2010) Treatment for glioblastoma multiforme: current guidelines and Canadian practice. Curr Oncol Tor Ont 17(6):52–58Google Scholar
  9. 9.
    Feuvret L, Noël G, Mazeron J-J, Bey P (2006) Conformity index: a review. Int J Radiat Oncol Biol Phys 64(2):333–342CrossRefGoogle Scholar
  10. 10.
    Hermanto U, Frija EK, Lii MJ, Chang EL, Mahajan A, Woo SY (2007) Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys 67(4):1135–1144CrossRefGoogle Scholar
  11. 11.
    Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C et al (2009) Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme–a dosimetric comparison. Radiat Oncol Lond Engl 4:57CrossRefGoogle Scholar
  12. 12.
    Buglione M, Spiazzi L, Saiani F, Costa L, Shehi B, Lazzari B et al (2014) Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk. Tumori 100(3):272–277PubMedGoogle Scholar
  13. 13.
    Briere TM, McAleer MF, Levy LB, Yang JN et al (2017) Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience. Radiat Oncol 12(1):79CrossRefGoogle Scholar
  14. 14.
    Mac Donald SM, Ahmad S, Kachris S, Vlachali MT et al (2007) Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys 8(2):47–60CrossRefGoogle Scholar
  15. 15.
    Fuller CD, Choi M, Forthuber B, Wang SJ, Rajagiriyil N, Salter BJ et al (2007) Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiat Oncol 2(1):26CrossRefGoogle Scholar
  16. 16.
    Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH et al (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64(3):892–897CrossRefGoogle Scholar
  17. 17.
    Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M et al (2010) A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. Int J Radiat Oncol Biol Phys 77(1):92–97CrossRefGoogle Scholar
  18. 18.
    Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, Osato K (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64(5):1317–1324CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyGeorges François Leclerc Cancer CenterDijonFrance
  2. 2.Department of StatisticsGeorges François Leclerc Cancer CenterDijonFrance
  3. 3.Department of Medical PhysicsGeorges François Leclerc Cancer CenterDijonFrance

Personalised recommendations